Cellectis Jövedelem

Mi az Cellectis Jövedelem?

A Jövedelem az Cellectis - -$113.27

Mi a Jövedelem meghatározása?

A közös részvényesek számára rendelkezésre álló nettó jövedelem egyenlő a nettó jövedelemmel mínusz a kifizetett előnyben részesített osztalékokkal.

Net income available to common shareholders are the profits remaining after the company pays all of its suppliers, employees, service providers, creditors, and preferred shareholders. In other words, this is revenue less all expenses and preferred dividends. The number measures common shareholders' claim on the company's cash flows.

Jövedelem a Health Care szektor a NASDAQ-on cégekben a Cellectis -hoz képest

Mit csinál Cellectis?

cellectis is a clinical-stage biopharmaceutical company focused on developing a new generation of cancer immunotherapies based on gene-edited t-cells (ucart). by capitalizing on its 18 years of expertise in gene editing – built on its flagship talen® technology and pioneering electroporation system pulseagile – cellectis uses the power of the immune system to target and eradicate cancer cells. using its life-science-focused, pioneering genome engineering technologies, cellectis’ goal is to create innovative products in multiple fields and with various target markets. cellectis is listed on the nasdaq market (ticker: clls) and on the nyse alternext market (ticker: alcls). to find out more about us, visit our website: www.cellectis.com talking about gene editing? we do it. talen® is a registered trademark owned by the cellectis group.

jövedelem -hoz hasonló cégek Cellectis